Scancell Holdings plc (SCNLF)
USD 0.13
(0.0%)
USD 0.13
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -11.38 Million GBP | -50.68% |
| 2022 | -7.31 Million GBP | 50.94% |
| 2021 | -9.63 Million GBP | -121.18% |
| 2020 | -6.73 Million GBP | -0.46% |
| 2019 | -6.7 Million GBP | -35.74% |
| 2018 | -4.91 Million GBP | -8.64% |
| 2017 | -4.51 Million GBP | -49.48% |
| 2016 | -3.02 Million GBP | -2.81% |
| 2015 | -2.93 Million GBP | -18.53% |
| 2014 | -2.45 Million GBP | -14.34% |
| 2013 | -2.13 Million GBP | -11.34% |
| 2012 | -1.92 Million GBP | -15.99% |
| 2011 | -1.7 Million GBP | 5.11% |
| 2010 | -1.78 Million GBP | -106.49% |
| 2009 | -863 Thousand GBP | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -3.92 Million GBP | 7.3% |
| 2024 Q2 | -3.92 Million GBP | 0.0% |
| 2023 Q3 | -4.83 Million GBP | 28.75% |
| 2023 FY | - GBP | -50.68% |
| 2023 Q1 | -856.5 Thousand GBP | 89.12% |
| 2023 Q2 | -6.78 Million GBP | -692.41% |
| 2023 Q4 | -4.23 Million GBP | 12.5% |
| 2022 Q2 | -5.65 Million GBP | -115.26% |
| 2022 FY | - GBP | 50.94% |
| 2022 Q4 | -7.86 Million GBP | -82.38% |
| 2022 Q3 | -4.31 Million GBP | 23.7% |
| 2022 Q1 | -2.62 Million GBP | 59.95% |
| 2021 Q2 | -2.94 Million GBP | -98.25% |
| 2021 Q4 | -6.56 Million GBP | -96.76% |
| 2021 Q3 | -3.33 Million GBP | -13.29% |
| 2021 Q1 | -1.48 Million GBP | 59.4% |
| 2021 FY | - GBP | -121.18% |
| 2020 FY | - GBP | -0.46% |
| 2020 Q3 | -1.83 Million GBP | 40.36% |
| 2020 Q4 | -3.65 Million GBP | -98.88% |
| 2020 Q2 | -3.08 Million GBP | -99.97% |
| 2020 Q1 | -1.54 Million GBP | -1.27% |
| 2019 Q1 | -1.83 Million GBP | -44.28% |
| 2019 FY | - GBP | -35.74% |
| 2019 Q2 | -1.83 Million GBP | 0.0% |
| 2019 Q3 | -1.52 Million GBP | 16.91% |
| 2019 Q4 | -1.52 Million GBP | 0.0% |
| 2018 Q2 | -1.18 Million GBP | -0.0% |
| 2018 Q4 | -1.26 Million GBP | 0.0% |
| 2018 Q1 | -1.18 Million GBP | 1.76% |
| 2018 FY | - GBP | -8.64% |
| 2018 Q3 | -1.26 Million GBP | -6.92% |
| 2017 Q4 | -1.2 Million GBP | 0.0% |
| 2017 Q1 | -1.04 Million GBP | -25.92% |
| 2017 Q2 | -1.04 Million GBP | 0.0% |
| 2017 Q3 | -1.2 Million GBP | -15.18% |
| 2017 FY | - GBP | -49.48% |
| 2016 FY | - GBP | -2.81% |
| 2016 Q2 | -677.26 Thousand GBP | 0.0% |
| 2016 Q3 | -833.37 Thousand GBP | -23.05% |
| 2016 Q4 | -833.37 Thousand GBP | 0.0% |
| 2016 Q1 | -677.26 Thousand GBP | 2.19% |
| 2015 Q2 | -773 Thousand GBP | 0.0% |
| 2015 Q3 | -692.43 Thousand GBP | 10.42% |
| 2015 FY | - GBP | -18.53% |
| 2015 Q1 | -773 Thousand GBP | -32.35% |
| 2015 Q4 | -692.43 Thousand GBP | 0.0% |
| 2014 Q3 | -584.08 Thousand GBP | 9.45% |
| 2014 Q1 | -645.04 Thousand GBP | -10.59% |
| 2014 Q4 | -584.08 Thousand GBP | 0.0% |
| 2014 FY | - GBP | -14.34% |
| 2014 Q2 | -645.05 Thousand GBP | -0.0% |
| 2013 Q4 | -583.28 Thousand GBP | 0.0% |
| 2013 FY | - GBP | -11.34% |
| 2013 Q3 | -583.28 Thousand GBP | 0.0% |
| 2012 FY | - GBP | -15.99% |
| 2011 FY | - GBP | 5.11% |
| 2010 FY | - GBP | -106.49% |
| 2009 FY | - GBP | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Qrons Inc. | -40.08 Thousand USD | -28302.485% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 79.429% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -550.515% |
| Adynxx, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 112.106% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -3000.041% |
| BioStem Technologies, Inc. | -7.55 Million USD | -50.709% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 34.462% |
| Skye Bioscience, Inc. | -13.54 Million USD | 15.97% |
| Rebus Holdings, Inc. | -951 Thousand USD | -1097.056% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -193.076% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1700.109% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 2258.378% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 28.266% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 83.974% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -92.008% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -4660.192% |
| SQZ Biotechnologies Company | -64.14 Million USD | 82.252% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -330.487% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -641.122% |
| Mesoblast Limited | -62.38 Million USD | 81.753% |
| Marizyme, Inc. | -34.28 Million USD | 66.793% |
| Genus plc | 73.7 Million USD | 115.446% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -72.184% |
| Pharming Group N.V. | 9.87 Million USD | 215.258% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -665.356% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -220.947% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -29.777% |
| ContraFect Corporation | -64.99 Million USD | 82.486% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -151.514% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -712.094% |
| IMV Inc. | -35.52 Million USD | 67.954% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -389.883% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -2097.488% |
| ONE Bio Corp. | 13.61 Million USD | 183.626% |
| Accustem Sciences Inc. | -3.74 Million USD | -203.864% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 76.395% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -798.407% |
| Q BioMed Inc. | -617.62 Thousand USD | -1743.181% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 418.701% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -398.317% |
| Biomind Labs Inc. | -1.03 Million USD | -1000.383% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 71.279% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -293.593% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -58.966% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 169403.986% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -45436.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -355.003% |
| GB Sciences, Inc. | -1.41 Million USD | -701.755% |
| Alpha Cognition Inc. | -9.7 Million USD | -17.293% |
| HST Global, Inc. | -5303.00 USD | -214570.941% |
| CSL Limited | 4.78 Billion USD | 100.238% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -453.427% |
| Halberd Corporation | -74.27 Thousand USD | -15226.001% |
| Enzolytics Inc. | -2.12 Million USD | -436.468% |
| Agentix Corp. | -1.37 Million USD | -729.885% |
| Resverlogix Corp. | -11.74 Million USD | 3.049% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -271.66% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 94.73% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1035.415% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 228.578% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -659.487% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 3104.931% |
| AVAX Technologies, Inc. | -6.11 Million USD | -86.237% |
| Zenith Capital Corp. | -8.6 Million USD | -32.28% |
| Genscript Biotech Corporation | -248.71 Million USD | 95.423% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -65246.421% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -365.325% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -6367.287% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -492.635% |
| Kadimastem Ltd | -2.62 Million USD | -333.778% |
| Helix BioMedix, Inc. | -1.04 Million USD | -988.012% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -6186.446% |
| LadRx Corporation | 412.28 Thousand USD | 2861.21% |
| Cell Source, Inc. | -4.27 Million USD | -166.447% |
| Regen BioPharma, Inc. | 1.46 Million USD | 876.558% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -1115.007% |
| NovAccess Global Inc. | -1.03 Million USD | -1000.119% |
| Affymax, Inc. | -14.29 Million USD | 20.364% |
| Itoco Inc. | -1.86 Million USD | -509.097% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -2898.788% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -920.072% |
| Mobile Lads Corp. | -2.24 Million USD | -407.951% |
| CytoDyn Inc. | -18.02 Million USD | 36.857% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -14304.839% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -92990.195% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -2243.94% |
| SYBLEU INC | -141.57 Thousand USD | -7941.195% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -971.93% |
| International Stem Cell Corporation | 202 Thousand USD | 5735.644% |
| Bioxytran, Inc. | -3.82 Million USD | -197.999% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -21526.14% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -362.401% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 68.262% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -25197.778% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -315.778% |
| Neutra Corp. | -181.24 Thousand USD | -6180.932% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 43.529% |
| PureTech Health plc | -11.62 Million USD | 2.09% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 43.525% |
| IXICO plc | -707 Thousand USD | -1510.184% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -48.133% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 76.453% |
| CSL Limited | 4.73 Billion USD | 100.241% |
| Cellectis S.A. | -92.63 Million USD | 87.711% |